Research on Cadherin-3 as a Biomarker for Early Diagnosis and Prognosis of Lung Cancer
DA Yueping1,2, ZHOU Binghan1, XU Rong1, JIN Jingzhuo1, SUN Aihua1*, TIAN Chunyan1*
This study aims to explore the potential of CDH3 (Cadherin-3) as a biomarker for early diagnosis and prognosis of lung cancer, and preliminarily investigate the mechanism of CDH3 in tumorigenesis and progression. By integrating proteomic and transcriptomic data from multiple public datasets, the expression differences of CDH3 between lung cancer and adjacent normal tissues and the correlation with survival were analyzed to evaluate its potential as a biomarker for early diagnosis and prognosis of lung cancer. CDH3 knockdown and overexpression lung cancer cell lines were constructed, conducted proteomic analysis, screened differentially expressed proteins, and performed functional pathway enrichment analysis. The effects of CDH3 on the biological behavior of lung cancer cells were validated through CCK8 proliferation assays, Transwell assays, and wound healing assays. Multi-omics analysis revealed that CDH3 is significantly overexpressed in early-stage lung cancer, and its high expression is associated with poor patient prognosis, indicating its potential as a biomarker for early diagnosis and prognosis of lung cancer. Proteomic data analysis of CDH3 overexpressed lung cancer cells suggested that CDH3 overexpression is related to pathways associated with tumor proliferation, migration, and invasion. In vitro experiments confirmed that knockdown of CDH3 weakens the proliferation, migration, and invasion abilities of H1975 cells, whereas overexpression of CDH3 enhances these abilities in H1299 cells. In summary, CDH3 is a promising biomarker for early diagnosis and prognosis in lung cancer, likely by promoting tumor cell proliferation, migration, and invasion to drive tumor progression.
CN
EN